Myovant Sciences Ltd. [NYSE: MYOV] traded at a low on 03/02/23, posting a -0.04 loss after which it closed the day’ session at $26.95. The company report on January 26, 2023 that Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 million.
Net product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022.
The results of the trading session contributed to over 2441468 shares changing hands. Over the past one week, the price volatility of Myovant Sciences Ltd. stands at 0.08% while the volatility over the past one month is 0.16%.
The market cap for MYOV stock reached $2.62 billion, with 96.86 million shares outstanding and 46.10 million shares in the current float. Compared to the average trading volume of 850.11K shares, MYOV reached a trading volume of 2441468 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Myovant Sciences Ltd. [MYOV]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MYOV shares is $27.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MYOV stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for Myovant Sciences Ltd. shares, keeping their opinion on the stock as In-line, with their previous recommendation back on October 26, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price from $12 to $23. The new note on the price target was released on August 09, 2022, representing the official price target for Myovant Sciences Ltd. stock. Previously, the target price had yet another raise to $24, while SVB Leerink analysts kept a Mkt Perform rating on MYOV stock.
The Average True Range (ATR) for Myovant Sciences Ltd. is set at 0.05, with the Price to Sales ratio for MYOV stock in the period of the last 12 months amounting to 6.91.
How has MYOV stock performed recently?
Myovant Sciences Ltd. [MYOV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.04. With this latest performance, MYOV shares gained by 0.26% in over the last four-week period, additionally plugging by 56.14% over the last 6 months – not to mention a rise of 105.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYOV stock in for the last two-week period is set at 56.36, with the RSI for the last a single of trading hit 55.23, and the three-weeks RSI is set at 59.12 for Myovant Sciences Ltd. [MYOV]. The present Moving Average for the last 50 days of trading for this stock 26.92, while it was recorded at 26.96 for the last single week of trading, and 20.72 for the last 200 days.
Myovant Sciences Ltd. [MYOV]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Myovant Sciences Ltd. [MYOV] shares currently have an operating margin of -81.11 and a Gross Margin at +76.35. Myovant Sciences Ltd.’s Net Margin is presently recorded at -89.18.
Myovant Sciences Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 1.60.
Insider trade positions for Myovant Sciences Ltd. [MYOV]
There are presently around $1,118 million, or 31.60% of MYOV stock, in the hands of institutional investors. The top three institutional holders of MYOV stocks are: FIL LTD with ownership of 8,624,543, which is approximately New of the company’s market cap and around 1.50% of the total institutional ownership; BELLEVUE GROUP AG, holding 5,910,639 shares of the stock with an approximate value of $159.29 million in MYOV stocks shares; and STATE STREET CORP, currently with $78.42 million in MYOV stock with ownership of nearly 44.321% of the company’s market capitalization.
Positions in Myovant Sciences Ltd. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 81 institutional holders increased their position in Myovant Sciences Ltd. [NYSE:MYOV] by around 26,328,948 shares. Additionally, 63 investors decreased positions by around 13,659,010 shares, while 11 investors held positions by with 1,490,049 shares. The mentioned changes placed institutional holdings at 41,478,007 shares, according to the latest SEC report filing. MYOV stock had 55 new institutional investments in for a total of 21,517,069 shares, while 35 institutional investors sold positions of 8,985,277 shares during the same period.